Phase 2 study of frontline bortezomib in patients with advanced non-small cell lung cancer-Reference-Cited by-同舟云学术

Phase 2 study of frontline bortezomib in patients with advanced non-small cell lung cancer

Published:2012-04 Issue:1 Volume:76 Page:78-83
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Besse Benjamin,Planchard David,Veillard Anne-Sophie,Taillade Laurent,Khayat David,Ducourtieux Muriel,Pignon Jean-Pierre,Lumbroso Jean,Lafontaine Carole,Mathiot Claire,Soria Jean-Charles

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference27 articles.

1. American society of clinical oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer;Azzoli;J Clin Oncol,2009

2. Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma;Mok;N Engl J Med,2009

3. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL;Reck;J Clin Oncol,2009

4. Paclitaxel–carboplatin alone or with bevacizumab for non-small-cell lung cancer;Sandler;N Engl J Med,2006

5. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer;Scagliotti;J Clin Oncol,2008

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Epigenetic Alterations as Vital Aspects of Bortezomib Molecular Action;Cancers;2023-12-23

2. Proteasome inhibitors in the treatment of nonsmall cell lung cancer: A systematic review of clinical evidence;Health Science Reports;2023-11

3. Clinical Experience on Proteasome Inhibitors in Cancer;Precision Cancer Therapies, Volume 1 ‐ Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies;2023-03-15

4. Overcoming immunosuppression and pro-tumor inflammation in lung cancer with combined IL-1β and PD-1 inhibition;Future Oncology;2022-09

5. miR-466 Contributes to the Enhanced Antitumor Effect of Bortezomib on Non-Small-Cell Lung Cancer by Inhibiting CCND1;Chemotherapy;2022